Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer 3Q10 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Pfizer 3Q10

Revenues in the quarter were boosted by $5.2 billion, or 44%, due to legacy Wyeth products, and negatively impacted by $458 million, or 4%, due to legacy Pfizer products, including the loss of exclusivity of Lipitor in Canada and Spain, as well as Camptos

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer 3Q10

3Q Revenues: $16.2 billion (+39%*)

3Q Earnings: $866 million (-70%*)

YTD Revenues: $50.2 billion (+50%*)

YTD Earnings: $5.4 billion (-32%*)

Comments: Revenues in the quarter were boosted by $5.2 billion, or 44%, due to legacy Wyeth products, and negatively impacted by $458 million, or 4%, due to legacy Pfizer products, including the loss of exclusivity of Lipitor in Canada and Spain, as well as Camptosar in Europe. U.S. revenues were $7.1 billion (+48%) and International revenues were $9.1 billion (+33%). Primary Care revenue was $5.7 billion (+2%). Specialty Care revenue was $3.7 billion (+136%). Established Products accounted for $2.2 billion (+31%). Emerging Markets revenue was $2.1 billion (+36%). Oncology sales were $335 million (-10%).

* All figures do not include Wyeth revenues or earnings from 2009.


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters